QNCX

Quince Therapeutics, Inc.

QNCX, USA

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

https://www.quincetx.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
QNCX
stock
QNCX

Citizens reiterates Market Outperform rating on Quince Therapeutics stock By Investing.com Investing.com Nigeria

Read more →
QNCX
stock
QNCX

Quince Therapeutics (QNCX) publishes eDSP lung, IBD data before Phase 3 results in 2026 Stock Titan

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$7.5

Analyst Picks

Strong Buy

3

Buy

1

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

214.99

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-1,269.31 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-12.23 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very Low

102.78

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 18.12% of the total shares of Quince Therapeutics, Inc.

1.

Nantahala Capital Management, LLC

(4.707%)

since

2025/06/30

2.

Vanguard Group Inc

(2.707%)

since

2025/06/30

3.

Vanguard Total Stock Mkt Idx Inv

(1.759%)

since

2025/07/31

4.

IEQ CAPITAL, LLC

(0.8178%)

since

2025/06/30

5.

Geode Capital Management, LLC

(0.7391%)

since

2025/06/30

6.

Renaissance Technologies Corp

(0.7071%)

since

2025/06/30

7.

Vanguard Institutional Extnd Mkt Idx Tr

(0.7054%)

since

2025/07/31

8.

Rockefeller Capital Management L.P.

(0.6313%)

since

2025/06/30

9.

BlackRock Inc

(0.625%)

since

2025/06/30

10.

HighTower Advisors, LLC

(0.5743%)

since

2025/06/30

11.

Fidelity Extended Market Index

(0.3644%)

since

2025/07/31

12.

Alphabet Inc

(0.3521%)

since

2025/06/30

13.

Shay Capital LLC

(0.2793%)

since

2025/06/30

14.

ADAR1 Capital Management LLC

(0.2661%)

since

2025/06/30

15.

Bridgeway Capital Management, LLC

(0.2394%)

since

2025/06/30

16.

State Street Corp

(0.2325%)

since

2025/06/30

17.

Mariner Wealth Advisors LLC

(0.228%)

since

2025/06/30

19.

Millennium Management LLC

(0.2061%)

since

2025/06/30

20.

Citadel Advisors Llc

(0.1748%)

since

2025/06/30

21.

Scharf Investments

(0.1695%)

since

2025/06/30

22.

iShares Micro-Cap ETF

(0.1497%)

since

2025/08/31

23.

Northern Trust Corp

(0.1443%)

since

2025/06/30

24.

Bridgeway Ultra-Small Company Market

(0.1358%)

since

2025/06/30

25.

Fidelity Total Market Index

(0.1159%)

since

2025/07/31

26.

Intellectus Partners, LLC

(0.0993%)

since

2025/06/30

27.

Fidelity Series Total Market Index

(0.0944%)

since

2025/07/31

28.

Northern Trust Extended Eq Market Idx

(0.0786%)

since

2025/06/30

29.

NT Ext Equity Mkt Idx Fd - L

(0.0786%)

since

2025/06/30

30.

Spartan Extended Market Index Pool F

(0.0769%)

since

2025/07/31

31.

Vanguard Instl Ttl Stk Mkt Idx InstlPls

(0.0651%)

since

2025/07/31

32.

Bridgeway Ultra-Small Company

(0.0624%)

since

2025/06/30

33.

NT Ext Equity Mkt Idx Fd - NL

(0.062%)

since

2025/06/30

34.

Extended Equity Market Fund K

(0.0559%)

since

2025/06/30

35.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0482%)

since

2025/06/30

36.

Fidelity Nasdaq Composite Index

(0.0472%)

since

2025/07/31

37.

Spartan Total Market Index Pool G

(0.0434%)

since

2025/07/31

38.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0222%)

since

2025/06/30

39.

Blackrock US Eq Mkt Fund CF

(0.0155%)

since

2025/07/31

40.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0151%)

since

2024/12/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.25

EPS Estimate

-0.2167

EPS Difference

-0.0333

Surprise Percent

-15.3669%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.3)
GARP
Not Attractive for GARP(0.5)
Growth
Weak Growth Prospect(0.5)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(1.5)
Value
Overpriced(2)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.